胸腔注射尿激酶治疗结核性胸膜炎89例临床分析
 |
| 第1页 |
参见附件。
摘 要：目的：探讨胸腔内注射尿激酶对结核性胸膜炎引起胸膜增厚、粘连的预防和治疗作用。方法：89例已确诊为结核性胸膜炎胸腔积液并存在纤维分隔患者，随机分为注药组(46例)和对照组(43例)，对照组予抗结核、胸腔置管引流等常规治疗，注药组在常规治疗治疗的基础上加用尿激酶胸腔内注射，观察比较两组抽液量、2周内胸水消失者比例、治疗2个月后胸膜厚度及胸膜粘连发生率。结果：注药组抽液总量(4353±586)ml，对照组(3423±538)ml，p<0.01，注药组2周内胸水消失者82.6%(38/46)，对照组48.9%(21/43)，P<0.01，治疗后2个月注药组胸膜厚度及胸膜粘连发生率分别为(1.85±0.72)mm、19.6%(9/46)，对照组为(3.68± 0.96)mm 、44.2%(19/43)，P<0.01。结论：腔内注入尿激酶可以显著增加结核性胸膜炎患者胸水引流量，缩短胸水吸收时间，有效防止胸膜增厚粘连的发生。
关键词：结核性胸膜炎 尿激酶 胸腔注射
Abstract：Observation and assessment the effect of prevention and treatment of pleural thickening， adhesion of tuberculous pleurisy by cavitas thoracis injection urokinase.Methods：The 89 cases，that were definited as tuberculous pleural effusion and fiber separationwere divided into urokinase therapy group(46cases)and control group (43cases).The control group was treated with antituberculosis drugs and drainaging of chest tube the therapy group was cavitas thoracis injected urokinase. The two groups were observed and compared ......
您现在查看是摘要介绍页，详见PDF附件。